Guizhou Yibai Pharmaceutical Co., Ltd.

Equities

600594

CNE000001H03

Pharmaceuticals

End-of-day quote Shanghai S.E. 23:00:00 23/05/2024 BST 5-day change 1st Jan Change
3.72 CNY +0.27% Intraday chart for Guizhou Yibai Pharmaceutical Co., Ltd. -9.27% -34.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
YiBai Pharma to Repurchase Up to 40 Million Yuan Shares MT
Guizhou Yibai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares. CI
Guizhou Yibai Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GuiZhou YiBai Pharma to Book 2022 Loss on Policy Changes, COVID-19 MT
Guizhou Yibai Pharmaceutical Completes Construction of $84.5 Million Factory MT
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guizhou Yibai Traditional Chinese Medicine Formula Granules Pharmaceutical Co., Ltd. announced that it expects to receive CNY 179.8539 million in funding from Guizhou Yibai Pharmaceutical Co., Ltd., Guizhou Province Agricultural and Rural Modernization Development Equity Investment Fund Partnership CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Guizhou Yibai Pharmaceutical Co., Ltd. completed the acquisition of 70% stake in Deyang Cancer Hospital Co., Ltd. from Deyang Foji Hospital Management Partnership (Limited Partnership), Deyang Foming Hospital Management Partnership (Limited Partnership) and Deyang Foxiang Management Hospital Partnership (Limited Partnership) CI
Guizhou Yibai Pharmaceutical Co., Ltd. signed an equity transfer agreement to acquire a 70% stake in Deyang Cancer Hospital Co., Ltd. from Deyang Foji Hospital Management Partnership (Limited Partnership), Deyang Foming Hospital Management Partnership (Limited Partnership) and Deyang Foxiang Management Hospital Partnership (Limited Partnership) for approximately CNY 340 million. CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Announces Cash Dividend for First Half of 2020, Payable September 2, 2020 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Announces Cash Dividend for 2019, Payable June 3, 2020 CI
Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Chart Guizhou Yibai Pharmaceutical Co., Ltd.
More charts
GUIZHOU YIBAI PHARMACEUTICAL CO., LTD is a China-based company, principally engaged in the production and distribution of pharmaceuticals. The Company provides prescription drugs and over the counter (OTC) products, including injections, capsules, oral liquid, granules and tablets, among others. The company's products are applied in the treatment of cancer, cardiovascular and cerebrovascular, orthopedics, digestion, gynecology, children and breathing, among others. The Company mainly conducts its businesses within domestic markets.
More about the company
  1. Stock Market
  2. Equities
  3. 600594 Stock
  4. News Guizhou Yibai Pharmaceutical Co., Ltd.
  5. Guizhou Yibai Pharmaceutical Completes Construction of $84.5 Million Factory